ZUMA-12

Background

Phase II multicenter single-arm study (ZUMA-12), N=40 with high-risk large B-cell lymphoma (high IPI and/or double-/triple-hit histology) and positive interim PET after 2 cycles of chemoimmunotherapy. Tested axicabtagene ciloleucel (axi-cel), autologous anti-CD19 CAR T, as part of first-line therapy.

Interventions and follow up

Treatment: Conditioning chemotherapy (cyclophosphamide/fludarabine) followed by a single infusion of axicabtagene ciloleucel (2×10^6 CAR T cells/kg) as first-line therapy.
Primary endpoint: Complete response rate (CRR) in efficacy-evaluable patients.
mFollow up: 15.9 months.

Results

CRR (primary): 78% (95% CI 62–90) in efficacy-evaluable patients (n=37).
ORR: 89% (95% CI 75–97).
DOR / EFS / PFS: median not reached; 73% remained in objective response at data cutoff.
OS: NR.

Adverse events

CRS: Grade ≥3 in 3 patients (8%); no grade 5 CRS.
Neurologic events: Grade ≥3 in 9 patients (23%); no treatment-related grade 5 events.
CAR T expansion: Robust in all patients (median time to peak 8 days).

Conclusions

Axi-cel as part of first-line therapy was highly effective in high-risk LBCL, achieving a 78% CRR with a manageable safety profile, supporting investigation of CAR T-cell therapy in earlier lines.

Key Limitations

Small single-arm study (N=40) without a comparator and relatively short follow-up. Surrogate endpoint (CRR); randomized data versus standard frontline chemoimmunotherapy needed before adopting CAR T as first-line standard.

Clinical Context

Axi-cel is FDA/EMA-approved for relapsed/refractory LBCL (second line and beyond per ZUMA-7). ZUMA-12 is proof-of-concept for frontline CAR T in high-risk disease; ESMO guidance currently reserves CAR T for relapsed/refractory disease pending randomized frontline data.

References